Review Article

Transcatheter versus Surgical Aortic Valve Replacement after Previous Cardiac Surgery: A Systematic Review and Meta-Analysis

Table 2

Baseline and echocardiography data of the included studies.

Year of publicationStortecky et al. [18]Wilbring et al. [19]Papadopoulos et al. [20]Nguyen et al. [21]Greason et al. [22]Wendt et al. [23]Conte et al. [24]
2011201320142014201420152015
Number of patients8010680255288113226
TAVRSAVRTAVRSAVRTAVRSAVRTAVRSAVRTAVRSAVRTAVRSAVRTAVRSAVR

Patients who underwent TAVR/SAVR4040535340401071481481406251115111
Age (mean ± SD)78.2 ± 670.6 ± 878.1 ± 5.577.6 ± 2.781 ± 480 ± 379.8 ± 7.972.5 ± 8.880.7 ± 782.3 ± 6.278.7 ± 5.971.1 ± 10.882 ± 5.881 ± 5.9
Body mass index (mean ± SD)27.4 ± 528 ± 527.9 ± 4.027.3 ± 4.2N/AN/A27.2 ± 528.4 ± 5.3N/AN/A27.1 ± 4.126.6 ± 3.7N/AN/A
Male (%)32 (80)33 (83)26 (65)35 (66)29 (73)29 (73)81 (75.7)116 (78.4)120 (81)111 (79)43 (69.4)38 (74.5)91 (79.1)87 (78.4)
Diabetes mellitus (%)19 (48)13 (33)28 (52.8)23 (43.4)17 (42)14 (35)48 (44.9)71 (48)74 (50)70 (50)24 (38.7)22 (43.1)49 (42.6)58 (52.3)
Systemic hypertension (%)34 (85)36 (90)N/AN/A16 (40)18 (45)105 (98.1)138 (93.2)N/AN/A57 (91.9)45 (88.2)N/AN/A
NYHA III/IV (%)26 (65)26 (65)N/AN/AN/AN/AN/AN/A140 (94.6)131 (93.6)N/AN/A96 (83.5)98 (88.3)
Coronary artery disease (%)40 (100)40 (100)53 (100)53 (100)33 (83)30 (75)86 (80.4)126 (85.1)148 (100)140 (100)N/AN/A115 (100)111 (100)
Myocardial infarction (%)20 (50)14 (35)N/AN/AN/AN/AN/AN/A60 (41)62 (45)N/AN/AN/AN/A
PCI (%)N/AN/AN/AN/AN/AN/AN/AN/A59 (40.4)50 (35.7)N/AN/A49 (42.6)50 (45)
Renal failure/dialysis (%)N/AN/A35 (66)32 (60.4)20 (50)16 (40)N/AN/AN/AN/A12 (23.5)13 (21)10 (8.7)8 (7.3)
Cerebrovascular disease (%)4 (10)6 (15)10 (18.9)8 (15.1)9 (23)8 (20)41 (38.3)45 (30.4)49 (35.5)40 (29.4)N/AN/A37 (32.7)32 (28.8)
Peripheral vascular disease (%)21 (53)9 (23)N/AN/A13 (33)11 (27)48 (44.9)42 (28.4)75 (50.7)67 (48.6)32 (52)15 (29.4)47 (41.6)57 (51.8)
COPD (%)7 (17.5)7 (17.5)5 (9.4)4 (7.5)9 (23)8 (20)55 (51.4)44 (29.7)67 (45.3)58 (41.4)16 (25)17 (33.3)48 (41.7)43 (38.7)
STS score (median or mean ± SD)7.6 ± 76.3 ± 6N/AN/A24 ± 619 ± 611.87.111.8 ± 3.312 ± 3.112 ± 107.1 ± 5.27.3 ± 2.78.0 ± 3.5
EuroSCORE (mean ± SD)33.5 ± 1720.2 ± 1429.9 ± 1426.4 ± 12.911.1 ± 2.810.4 ± 3N/AN/A34.6 ± 16.833.8 ± 15.336.4 ± 17.422.2 ± 17.525.6 ± 16.224.2 ± 15.8
Previous CABG (%)40 (100)40 (100)48 (90.6)49 (92.4)N/AN/A107 (100)148 (100)148 (100)140 (100)59 (95.2)36 (70.6)115 (100)111 (100)
Previous AVR (%)005 (9.4)4 (7.6)N/AN/A00002 (3.2)10 (19.6)00
Other cardiac surgery (%)0000N/AN/A00001 (1.6)5 (9.8)00
Mean AVA (cm2) (mean ± SD)N/AN/AN/AN/A0.63 ± 0.290.68 ± 0.310.7 ± 0.120.76 ± 0.230.68 ± 0.20.66 ± 0.2N/AN/AN/AN/A
MAVPG (mmHg) (mean ± SD)39 ± 1548.6 ± 1644 ± 455 ± 1057 ± 2151 ± 1643.3 ± 13.042.0 ± 12.665.9 ± 20.368.9 ± 22.2N/AN/AN/AN/A
LVEF % (mean ± SD)46.5 ± 1549.8 ± 14N/AN/A48 ± 1447 ± 1243.3 ± 13.146.9 ± 14.850.4 ± 13.352.2 ± 11.548.1 ± 1349.9 ± 12.3N/AN/A

TAVR/SAVR, transcatheter/surgical aortic valve replacement; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting; AVA, aortic valve area; MAVPG, mean aortic valve pressure gradient.